Last reviewed · How we verify
TRIPLE SULFA (TRIPLE SULFA (SULFABENZAMIDE)
TRIPLE SULFA (generic name: TRIPLE SULFA (SULFABENZAMIDE) is a drug developed by PHARMADERM. It is currently FDA-approved.
TRIPLE SULFA is a small molecule with an unknown mechanism of action. It is also known by the synonyms NSC-74587, SULFABENZAMIDA, SULFABENZAMIDE, and SULFABENZAMIDE.
At a glance
| Generic name | TRIPLE SULFA (SULFABENZAMIDE |
|---|---|
| Sponsor | PHARMADERM |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRIPLE SULFA CI brief — competitive landscape report
- TRIPLE SULFA updates RSS · CI watch RSS
- PHARMADERM portfolio CI
Frequently asked questions about TRIPLE SULFA
What is TRIPLE SULFA?
TRIPLE SULFA (TRIPLE SULFA (SULFABENZAMIDE) is a pharmaceutical drug developed by PHARMADERM.
Who makes TRIPLE SULFA?
TRIPLE SULFA is developed and marketed by PHARMADERM (see full PHARMADERM pipeline at /company/pharmaderm).
What is the generic name of TRIPLE SULFA?
TRIPLE SULFA (SULFABENZAMIDE is the generic (nonproprietary) name of TRIPLE SULFA.
What development phase is TRIPLE SULFA in?
TRIPLE SULFA is FDA-approved (marketed).
Related
- Manufacturer: PHARMADERM — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing